Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics

David Z. D'Argenio · Marc R. Gastonguay ·
Richard C. Brundage · Raymond Miller ·
Stacey J. Tannenbaum · Marc Pfister

Published online: 5 January 2012
© Springer Science+Business Media, LLC 2012

In 1982, the Journal of Pharmacokinetics and Pharmacodynamics first gave voice to the discipline of pharmacometrics [1] by providing a forum for the scholarly contributions that were seminal to the early development of this new field of study. In the intervening years, pharmacometrics has expanded far beyond its initial focus on the analysis of measurements (metrics) in pharmacokinetics and biopharmaceutics to become a quantitative science that encompasses a spectrum of activities from basic research into disease and mechanisms of drug action through the rational use of medicines in patient care [2]. During this time, the Journal has continued to serve as the intellectual home for new advances in pharmacokinetics and pharmacodynamics, as well as in pharmacometrics. Because of this history, the American Society of Pharmacometrics (ASoP) and the Journal of Pharmacokinetics and Pharmacodynamics have inaugurated an affiliation designating the Journal as an official publication of ASoP.

D. Z. D'Argenio (✉)
University of Southern California, Los Angeles, CA, USA
e-mail: dargenio@bmsr.usc.edu

M. R. Gastonguay
Metrum Research Group, Tariffville, CT, USA

R. C. Brundage
University of Minnesota, Minneapolis, MN, USA

R. Miller
Daiichi Sankyo, Edison, NJ, USA

S. J. Tannenbaum
Astellas, Deerfield, IL, USA

M. Pfister
Quantitative Solutions, Bridgewater, NJ, USA

This strategic partnership with the Journal of Pharmacokinetics and Pharmacodynamics is representative of ASoP's mission to promote the central role of pharmacometrics in advancing the discovery, development, and utilization of new and existing medicines for the treatment and prevention of disease. This role is characterized by three concepts: (i) quantitative *integration* of multi-source data and knowledge through the application of clinical, biomedical, biological, engineering, statistical, and mathematical concepts, resulting in (ii) continuous methodological and technological *innovation*, supporting new scientific understanding and knowledge, which in turn (iii) *impacts* research, discovery, development, decision making, approval, and utilization of medicines [2].

Together with the Editor-in-Chief of the Journal, Professor William Jusko, we are happy to announce that Dr. Peter Bonate will be ASoP's designated Associate Editor to the Journal of Pharmacokinetics and Pharmacodynamics. Peter's own scholarly contributions to the field of pharmacometrics together with his extensive industry experience provide him with a unique perspective on the innovations needed to advance the methodologies and impact of pharmacometrics. Under Peter's collaborative leadership, the affiliation between ASoP and the Journal of Pharmacokinetics and Pharmacodynamics will accelerate the Society's efforts to serve its membership and advance its vision for the discipline of pharmacometrics.

References

1. Benet LZ, Rowland M (1982) Pharmacometrics: a new journal section. J Pharmacokin Biopharm 10:349–350
2. Pfister M, D'Argenio DZ (2010) The emerging scientific discipline of pharmacometrics. J Clin Pharmacol 50:6S